000172664 001__ 172664
000172664 005__ 20210129214457.0
000172664 0247_ $$2doi$$a10.1111/ene.12621
000172664 0247_ $$2WOS$$aWOS:000351398900008
000172664 0247_ $$2altmetric$$aaltmetric:3010711
000172664 0247_ $$2pmid$$apmid:25534579
000172664 037__ $$aFZJ-2014-06118
000172664 082__ $$a610
000172664 1001_ $$0P:(DE-HGF)0$$aPetrelli$$b0$$eCorresponding Author
000172664 245__ $$aCognitive training in Parkinson’s disease reduces cognitive decline in the long-term.
000172664 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2015
000172664 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1427450932_24554
000172664 3367_ $$2DataCite$$aOutput Types/Journal article
000172664 3367_ $$00$$2EndNote$$aJournal Article
000172664 3367_ $$2BibTeX$$aARTICLE
000172664 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000172664 3367_ $$2DRIVER$$aarticle
000172664 520__ $$aBackground and purposePatients with Parkinson's disease (PD) are at high risk for cognitive dysfunction. Non-pharmacological interventions have attracted increasing interest for enhancing PD patients' cognitive functions.MethodsOne-year follow-up data (T2) of a randomized controlled trial evaluating two 6-week cognitive trainings – a structured (NEUROvitalis, NV) and an unstructured (mentally fit, MF) program − compared with a waiting list control group (CG) in non-demented PD patients (Hoehn and Yahr I–III) are presented. Forty-seven PD patients were examined at T2. Effects on overall cognitive functions (Mini-Mental State Examination and DemTect) were compared between all groups with repeated measurement analyses of variance. A combined score of the percentage change value from baseline (T0) to T2 was calculated to identify patients who retained or improved their cognitive state (responders). The risk of developing mild cognitive impairment (MCI) was analyzed.ResultsSignificant time × treatment effects on overall cognitive functions were found for both training groups, each compared separately to the CG (DemTect, P < 0.05). Nine patients (56.3%) of the NV group, seven (41.2%) of the MF group and three (21.4%) of the CG were responders. Comparing NV to CG the odds ratio was 4.7 [95% confidence interval (0.8; 33.3)], and comparing MF to CG it was 2.6 [95% confidence interval (0.4; 17.4)]. MCI risk for patients without prior MCI was 40.0% in CG, 18.2% in MF and 18.2% in NV. The odds ratio was 3 comparing NV to CG, MF to CG.DiscussionThis study gives evidence that cognitive training may be effective to prevent cognitive decline and onset of MCI in PD patients.
000172664 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000172664 7001_ $$0P:(DE-HGF)0$$aKaesberg, S.$$b1
000172664 7001_ $$0P:(DE-Juel1)131613$$aBarbe, Michael$$b2
000172664 7001_ $$0P:(DE-HGF)0$$aTimmermann, L.$$b3
000172664 7001_ $$0P:(DE-HGF)0$$aRosen, J.$$b4
000172664 7001_ $$0P:(DE-Juel1)131720$$aFink, G. R.$$b5
000172664 7001_ $$0P:(DE-HGF)0$$aKessler, J.$$b6
000172664 7001_ $$0P:(DE-HGF)0$$aKalbe, E.$$b7$$eCorresponding Author
000172664 773__ $$0PERI:(DE-600)2020241-6$$a10.1111/ene.12621$$n4$$p640–647$$tEuropean journal of neurology$$v22$$x1351-5101$$y2015
000172664 909CO $$ooai:juser.fz-juelich.de:172664$$pVDB
000172664 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131613$$aForschungszentrum Jülich GmbH$$b2$$kFZJ
000172664 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich GmbH$$b5$$kFZJ
000172664 9130_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000172664 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000172664 9141_ $$y2015
000172664 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000172664 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000172664 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000172664 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000172664 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000172664 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000172664 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000172664 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000172664 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000172664 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF <  5
000172664 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000172664 980__ $$ajournal
000172664 980__ $$aVDB
000172664 980__ $$aI:(DE-Juel1)INM-3-20090406
000172664 980__ $$aUNRESTRICTED